Genprex (NASDAQ:GNPX) Shares Down 6% – Time to Sell?

Genprex (NASDAQ:GNPX)’s share price traded down 6% during mid-day trading on Monday . The company traded as low as $6.72 and last traded at $7.21. Approximately 27,461 shares changed hands during trading, a decline of 10% from the average session volume of 30,610 shares. The stock had previously closed at $7.67.

Analyst Ratings Changes

GNPX has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. Wall Street Zen raised shares of Genprex from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Genprex Trading Down 6.0%

The company has a 50 day moving average price of $13.80 and a 200-day moving average price of $31.41. The company has a market cap of $3.68 million, a P/E ratio of -0.51 and a beta of -0.92.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($14.08) earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Susquehanna International Group LLP lifted its holdings in shares of Genprex by 11.7% in the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after acquiring an additional 35,661 shares during the last quarter. Mayflower Financial Advisors LLC bought a new stake in shares of Genprex during the 1st quarter valued at approximately $36,000. Finally, Manchester Financial Inc. bought a new stake in shares of Genprex during the 1st quarter valued at approximately $36,000. Institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.